Skip to Content

Once-Weekly Semaglutide Promising for Weight Loss

THURSDAY, Feb. 11, 2021 -- Individuals with overweight or obesity receiving once-weekly subcutaneous semaglutide plus lifestyle intervention achieved sustained, clinically relevant reductions in body weight, according to a study published online Feb. 10 in the New England Journal of Medicine.

John P. H. Wilding, D.M., from the University of Liverpool in the United Kingdom, and colleagues enrolled 1,961 adults with a body mass index of 30 or greater who did not have diabetes and randomly assigned them to 68 weeks of either once-weekly subcutaneous semaglutide or placebo plus lifestyle intervention in a 2:1 ratio.

The researchers found that the mean change in body weight from baseline to week 68 was −14.9 and −2.4 percent in the semaglutide and placebo groups, respectively, for an estimated treatment difference of −12.4 percent. At week 68, compared with the placebo group, more participants in the semaglutide group achieved weight loss of 5 percent or more (86.4 versus 31.5 percent), 10 percent or more (69.1 versus 12.0 percent), and 15 percent or more (50.5 versus 4.9 percent). With respect to cardiometabolic risk factors, participants who received semaglutide had greater improvement than those receiving placebo. The most common adverse events with semaglutide were nausea and diarrhea, which were typically transient, were mild to moderate in severity, and decreased with time.

"The STEP 1 trial (like its name) is a good beginning," write the authors of an accompanying editorial. "However, as noted by the authors, there are concerns, including adverse events."

The study was funded by Novo Nordisk, the manufacturer of semaglutide.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

© 2021 HealthDay. All rights reserved.

Posted: February 2021

Read this next

Polynesian Ancestry May Increase Cardiometabolic Risk

WEDNESDAY, Feb. 24, 2021 -- Polynesian ancestry in Native Hawaiians seems to be associated with an increased risk for obesity, type 2 diabetes, and heart failure, according to a...

Prevalence of Multiple Chronic Conditions Up Among Veterans

TUESDAY, Feb. 23, 2021 -- The prevalence of multiple chronic conditions (MCC) is higher for male and female veterans versus nonveterans, according to a study published online Feb....

Proinflammatory, Low-Quality Maternal Diet Linked to Adiposity

MONDAY, Feb. 22, 2021 -- A proinflammatory, low-quality maternal diet may be associated with childhood adiposity, according to a study published online Feb. 22 in BMC...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.